research Alopecia areata and tofacitinib: a prospective multicenter study from a Saudi population
Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.
Search
for
Sort by
Research
690-720 / 1000+ results 
research Oral Tofacitinib and Systemic Corticosteroids, Alone or in Combination, in Patients With Moderate-to-Severe Alopecia Areata: A Retrospective Study
Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.
research Cutaneous lupus concerns from the patient perspective: a qualitative study
Patients with cutaneous lupus are most concerned about self-consciousness, physical symptoms, and disease progression.
research Effects of a gintonin-enriched fraction on hair growth: an in vitro and in vivo study
Gintonin-enriched fraction promotes hair growth and could be a potential alopecia treatment.
research Biallelic Variants in Lanosterol Synthase (LSS) Cause Palmoplantar Keratoderma-Congenital Alopecia Syndrome Type 2
Certain genetic changes in the LSS gene cause a rare skin and hair condition.
research Measuring Patient Quality of Life Following Treatment for Alopecia
Alopecia treatments improve life quality but side effects can lessen this benefit; better use of quality of life measures is needed.
research Assessing the role of stressful life events in the induction and recurrence of alopecia areata: A case-control study
Stress can trigger or worsen alopecia areata.
research Successful Treatment of Alopecia Areata Barbae with Platelet-rich Plasma
Platelet-rich plasma injections can effectively treat alopecia areata barbae.
research Decreased CD19+CD24hiCD38hi Regulatory B Cells in Alopecia Areata
Alopecia areata patients have fewer protective regulatory B cells, which may contribute to the disease.
research Prevalence and treatment of Alopecia areata in Taif area, KSA
Alopecia areata in Taif is common, mainly immune-related, and best treated with topical corticosteroids and vitamins.
research Clinical Presentations and Comorbidities of Pediatric Alopecia Areata
Pediatric alopecia areata needs more research to understand its characteristics and related conditions.
research Association between genetically predicted leukocyte telomere length and non-scarring alopecia: A two-sample Mendelian randomization study
Shorter telomeres in white blood cells may increase the risk of a common type of hair loss.
research Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm
CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.
research Factors associated with quality of life in patients with central centrifugal cicatricial alopecia: A cross-sectional study
Younger age, longer disease duration, frequent wig use, and lower education levels worsen quality of life in CCCA patients.
research Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel
Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.
research The Multi-Faceted Role of Gut Microbiota in Alopecia Areata
Gut bacteria may influence hair loss in alopecia areata.
research Treatment Response to Diphenylcyclopropenone in Patients with Alopecia Totalis/Universalis
DPCP can help regrow hair in some people with severe alopecia.
research Differentiation of frontal fibrosing alopecia and Lichen planopilaris on trichoscopy: A comprehensive review
Trichoscopy helps tell apart Frontal Fibrosing Alopecia and Lichen planopilaris by showing different hair and scalp features.
research Atopic diseases and the risk of alopecia areata among pre-teens and teenagers in Taiwan
Children with atopic diseases have a higher risk of developing alopecia areata.
research Alopecia areata: trichoscopic markers in determining disease activity
Exclamation mark hairs and broken hairs best indicate active alopecia areata.
research Telogen Effluvium: Is There a Need for a New Classification A Reply
Alfredo Rebora suggests a simpler classification for hair loss and a new test for easier diagnosis.
research A disproportionality analysis of adverse events caused by pexidartinib from the FDA adverse event reporting system
Pexidartinib often causes liver issues and fatigue, especially in women.
research Comorbid Bronchial Asthma, Atopic Dermatitis and Hashimoto's Thyroiditis Are Risk Factors for Early‐Onset, Severe and Prolonged Alopecia Areata
Having asthma, atopic dermatitis, or Hashimoto's thyroiditis increases the risk of severe and long-lasting alopecia areata.
research Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata
Ritlecitinib is an effective new treatment for Alopecia Areata.
research Relationship of Hair Regrowth Pattern in Alopecia Areata Patches According to DIMT Classification with Treatment Modalities and Patch Size: A Retrospective Cross-Sectional Analysis
Treatment type and patch size affect hair regrowth patterns in alopecia areata.
research Association of resilience and perceived stress in patients with alopecia areata: A cross-sectional study
People with alopecia who are more resilient tend to feel less stressed.
research Short Snips: YouT ube Shorts Recommendations for Hair Loss and Alopecia
Minoxidil is the most recommended treatment for hair loss on YouTube Shorts.
research Dermoscopy of neoplastic alopecia secondary to cutaneous metastasis from breast carcinoma
Recognizing specific scalp patterns can help diagnose hair loss linked to breast cancer spread.
research Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2
Baricitinib helps improve hair growth in severe alopecia, with better results in less severe cases and higher doses working faster.
research Alopecia Areata in Skin of Color Patients: New Considerations Sparked by the Approval of Baricitinib
The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.